Alpha 2.0
Login Register
» Authors » Atul Deodhar

Atul Deodhar

Explore the profile of Atul Deodhar including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 246
Citations 5698
Followers 0
Related Specialties
Rheumatology
General Medicine
Rehabilitation Medicine
Top 10 Co-Authors
Desiree van der Heijde
Xenofon Baraliakos
Lianne S Gensler
Philip J Mease
Walter P Maksymowych
Filip Van den Bosch
Jurgen Braun
Joachim Sieper
Denis Poddubnyy
Elizabeth C Hsia
Published In
Clin Rheumatol
J Rheumatol
Ann Rheum Dis
RMD Open
Arthritis Rheumatol
Affiliations
Soon will be listed here.
Recent Articles
21.
Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis
Navarro-Compan V, Deodhar A, Bahiri R, Bushmakin A, Cappelleri J, Rammaoui J
Arthritis Res Ther . 2024 May; 26(1):105. PMID: 38790040
Background: Tofacitinib is an oral Janus kinase inhibitor for treatment of ankylosing spondylitis (AS). Time to improvement in core domains of AS was estimated in tofacitinib-treated patients with AS. Methods:...
22.
Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial
Van den Bosch F, Deodhar A, Poddubnyy D, Maksymowych W, van der Heijde D, Kim T, et al.
ACR Open Rheumatol . 2024 May; 6(8):470-480. PMID: 38747163
Objective: Upadacitinib improved the signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) versus placebo over 14 weeks in the primary analysis of the SELECT-AXIS 2 nr-axSpA study. Here, we evaluated...
23.
Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status
Rudwaleit M, Deodhar A, Bauer L, Gensler L, Hoepken B, Kumke T, et al.
RMD Open . 2024 May; 10(2). PMID: 38724259
Objective: There is a paucity of data on long-term clinical responses in patients with non-radiographic axial spondyloarthritis (nr-axSpA) based on their baseline objective signs of inflammation such as MRI or...
24.
Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data
Kristensen L, Deodhar A, Leung Y, Vranic I, Mortezavi M, Fallon L, et al.
Rheumatol Ther . 2024 May; 11(3):487-499. PMID: 38696034
In this commentary, we review clinical data which helps inform individualized benefit-risk assessment for tofacitinib in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS). ORAL Surveillance, a safety trial...
25.
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
Navarro-Compan V, Ramiro S, Deodhar A, Mease P, Rudwaleit M, de la Loge C, et al.
RMD Open . 2024 Apr; 10(2). PMID: 38599650
Objective: To assess how achievement of increasingly stringent clinical response criteria and disease activity states at week 52 translate into changes in core domains in patients with non-radiographic (nr-) and...
26.
Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head-to-Head Randomized Phase IIIb Study
Baraliakos X, Ostergaard M, Poddubnyy D, van der Heijde D, Deodhar A, Machado P, et al.
Arthritis Rheumatol . 2024 Apr; 76(8):1278-1287. PMID: 38556921
Objective: Spinal radiographic progression is an important outcome in radiographic axial spondyloarthritis (SpA). The objective of the phase IIIb SURPASS study was to compare spinal radiographic progression in patients with...
27.
Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial
Strand V, Gossec L, Coates L, Ogdie A, Choi J, Becker B, et al.
Arthritis Care Res (Hoboken) . 2024 Mar; 76(8):1139-1148. PMID: 38529674
Objective: Deucravacitinib, a tyrosine kinase 2 inhibitor, was assessed in a phase 2 trial in patients with active psoriatic arthritis (PsA). Here, we report effects of deucravacitinib from the patient...
28.
Combination biologics or targeted synthetic disease-modifying anti-rheumatic drugs in the treatment of spondyloarthritis: a systematic literature review
Abedalweli R, Nguyen M, Deodhar A
Expert Rev Clin Immunol . 2024 Mar; 20(7):735-743. PMID: 38512065
Introduction: The advent of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have transformed the management of immune-mediated rheumatic diseases, including spondylarthritis (SpA). However, the data about combining b/ts DMARDs...
29.
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis
Rahman P, McInnes I, Deodhar A, Schett G, Mease P, Shawi M, et al.
Clin Rheumatol . 2024 Mar; 43(5):1591-1604. PMID: 38472528
Objectives: To evaluate the association between enthesitis resolution (ER) and dactylitis resolution (DR) and meaningful improvements in patient-reported outcomes (PROs) among biologic-naïve patients with PsA receiving guselkumab in the DISCOVER-2...
30.
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials
Sun R, Bustamante M, Gurusamy V, Lebwohl M, Gottlieb A, Mease P, et al.
Dermatol Ther (Heidelb) . 2024 Mar; 14(3):729-743. PMID: 38451423
Introduction: Secukinumab is an anti-interleukin (IL)-17A monoclonal antibody indicated for multiple immunological disorders. Here, we aim to summarize secukinumab safety in clinical trials (CTs) and post-marketing setting (PMS) until 25 ...